International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	BLINATUMOMAB IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: MECHANISM OF ACTION, CLINICAL RELEVANCE, AND EMERGING THERAPEUTIC PERSPECTIVES
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5637
RECEIVED	11 March 2026
ACCEPTED	02 June 2026
PUBLISHED	16 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

BLINATUMOMAB IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: MECHANISM OF ACTION, CLINICAL RELEVANCE, AND EMERGING THERAPEUTIC PERSPECTIVES

Ewa Jachimczak *(Corresponding Author, Email: jewa3392@gmail.com)*
University Hospital in Krakow, Poland
ORCID ID: 0009-0009-6899-3460

Vanessa Gąsiorowska
Our Lady of Perpetual Help Hospital, Wołomin, Poland
ORCID ID: 0009-0008-2420-627X

Paulina Jaruga
Regional Specialized Hospital No. 4, Bytom, Poland
ORCID ID: 0009-0009-3178-3785

Karolina Grodkowska
Municipal Hospital in Zabrze, Poland
ORCID ID: 0009-0000-6179-7242

Ewa Wojtanowska
Medical University of Lodz, Poland
ORCID ID: 0009-0007-4813-9473

Julia Kozicka
Medical University of Lodz, Poland
ORCID ID: 0009-0003-8138-6231

Julia Paczyna
Regional Specialized Hospital No. 4, Bytom, Poland
ORCID ID: 0009-0006-5485-7167

Marcin Mazur
Medical University of Lodz, Poland
ORCID ID: 0009-0008-2408-2107

Natalia Smyczyńska
Independent Complex of Public Outpatient Healthcare Facilities, Warsaw Praga-North, Poland
ORCID ID: 0009-0008-8213-3531

Mateusz Michalak
Medical University of Warsaw, Poland
ORCID ID: 0009-0002-5495-4670

ABSTRACT

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and despite significant improvements in survival with intensive chemotherapy, relapse and minimal residual disease (MRD) remain major clinical challenges.
Blinatumomab is a bispecific T-cell engager (BiTE) antibody targeting CD19-positive B-cell precursor ALL. By simultaneously binding CD3 on T lymphocytes and CD19 on leukemic cells, it enables major histocompatibility complex (MHC)-independent activation of cytotoxic T cells and targeted elimination of malignant cells.
Clinical studies have demonstrated that blinatumomab is effective in inducing remission in relapsed or refractory pediatric ALL and in achieving molecular remission in MRD-positive patients. Compared with conventional chemotherapy, it shows improved efficacy and a more favorable toxicity profile, although cytokine release syndrome and neurotoxicity remain clinically relevant adverse events.
Blinatumomab is increasingly used as a bridge to hematopoietic stem cell transplantation and is being investigated in combination regimens and earlier treatment settings. However, therapeutic resistance, including CD19 antigen loss and T-cell dysfunction, remains a limitation.
Overall, blinatumomab represents a significant advancement in immunotherapy for pediatric ALL, bridging conventional chemotherapy and cellular therapies such as CAR-T.

KEYWORDS

Blinatumomab, Acute Lymphoblastic Leukemia, Immunotherapy, CD19, BiTE, Pediatric Oncology

CITATION

Ewa Jachimczak, Vanessa Gąsiorowska, Paulina Jaruga, Karolina Grodkowska, Ewa Wojtanowska, Julia Kozicka, Julia Paczyna, Marcin Mazur, Natalia Smyczyńska, Mateusz Michalak. (2026) Blinatumomab in Pediatric Acute Lymphoblastic Leukemia: Mechanism of Action, Clinical Relevance, and Emerging Therapeutic Perspectives. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5637

Introduction

Acute lymphoblastic leukemia is a heterogeneous group of hematological malignancies arising from the clonal proliferation of immature B- or T-cell precursors. The disease is driven by complex genetic and epigenetic alterations that impair differentiation and promote uncontrolled proliferation of leukemic blasts [1,2]. Progressive replacement of normal hematopoiesis in the bone marrow leads to pancytopenia, clinically manifested by anemia, bleeding tendency, and increased susceptibility to infections.

A characteristic feature of ALL is its propensity for extramedullary dissemination. Leukemic blasts commonly infiltrate the liver, spleen, and lymph nodes, but may also involve the central nervous system, testes, skin, and other tissues, which has important implications for both diagnosis and risk-adapted therapy [2]. In neonates, a distinctive cutaneous manifestation known as the “blueberry muffin” rash may occur, reflecting dermal infiltration by malignant cells and extramedullary hematopoiesis.

ALL is the most common malignancy in childhood, accounting for approximately 25–30% of all pediatric cancers. The highest incidence occurs between 2 and 5 years of age, suggesting a significant contribution of developmental susceptibility and environmental exposures to disease initiation [2]. The introduction of risk-adapted, multi-agent chemotherapy protocols has led to substantial improvements in outcomes, with long-term survival rates now exceeding 85% in pediatric populations.

Despite these advances, relapse and treatment-resistant disease remain major clinical challenges. Relapsed ALL, particularly in cases of early relapse or extramedullary involvement, is associated with a markedly poor prognosis and limited therapeutic options [2]. In this setting, intensification of conventional chemotherapy often provides diminishing benefit while significantly increasing systemic toxicity, highlighting the need for alternative therapeutic strategies.

Minimal residual disease (MRD) has emerged as a central prognostic and therapeutic biomarker in ALL. It is defined as the presence of leukemic cells below the detection threshold of conventional microscopy but identifiable using highly sensitive methods such as multiparameter flow cytometry or molecular techniques

[4,5]. MRD status strongly correlates with relapse risk and overall survival and has become a key determinant of treatment stratification and response assessment.

In addition to tumor burden, the bone marrow microenvironment plays a critical role in leukemogenesis and therapeutic resistance. It represents a dynamic regulatory niche composed of stromal cells, endothelial compartments, cytokine networks, and both effector and suppressor immune cell populations that collectively influence leukemic cell survival [2]. Leukemic blasts actively remodel this microenvironment, promoting immune escape through mechanisms such as expansion of regulatory T cells (Tregs), secretion of immunosuppressive cytokines including IL-10 and TGF-β, inhibition of cytotoxic T-cell function, and disruption of antigen presentation pathways. These processes contribute to the formation of an immunosuppressive niche that may reduce the effectiveness of immunotherapeutic approaches, including T-cell–redirecting therapies.

In recent years, immunotherapy has emerged as a transformative strategy in the treatment of hematological malignancies [6, 21]. Unlike conventional chemotherapy, which exerts non-specific cytotoxic effects, immunotherapeutic approaches harness the specificity and adaptability of the immune system to selectively eliminate malignant cells [6]. Key modalities include monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor T-cell (CAR-T) therapy, all of which aim to enhance or redirect cytotoxic immune responses against leukemic cells.

A central molecular target in B-cell precursor ALL is the CD19 antigen, which is consistently expressed across most stages of B-cell differentiation and retained in the majority of leukemic blasts. This stable expression profile has established CD19 as a cornerstone target for immunotherapeutic strategies, enabling highly specific immune-mediated cytotoxicity with limited off-target effects [6]. Among CD19-directed therapies, blinatumomab—a bispecific CD19/CD3 T-cell engager—has gained particular clinical relevance due to its ability to directly link cytotoxic T lymphocytes with malignant B cells, bypassing classical antigen presentation mechanisms.

Review methods

A narrative literature review was conducted to synthesize current evidence regarding the mechanism of action, clinical efficacy, safety profile, and therapeutic positioning of blinatumomab in pediatric acute lymphoblastic leukemia.

A structured search strategy was applied using PubMed, Scopus, and Web of Science databases, including publications available up to 2025. The following keywords were used in various combinations: “blinatumomab”, “acute lymphoblastic leukemia”, “ALL”, “bispecific T-cell engager”, “BiTE”, “CD19”, “minimal residual disease”, and “CAR-T therapy”.

Peer-reviewed original studies, clinical trials, meta-analyses, and review articles were included. Priority was given to studies involving pediatric populations; however, relevant adult data were also incorporated where pediatric evidence remained limited.

Articles were selected based on their relevance to immunological mechanisms, clinical efficacy, safety outcomes, and therapeutic strategies in ALL. Non-English publications, case reports lacking broader clinical applicability, and preclinical studies without clear translational relevance were excluded.

Given the narrative nature of this review, no formal meta-analysis or quantitative synthesis was performed.

Blinatumomab – Molecular Characteristics and Mechanism of Action

Molecular Characteristics

Blinatumomab is the first clinically approved bispecific T-cell engager (BiTE) antibody designed to directly link immune effector cells with malignant B-lineage cells [7]. Its structure consists of two single-chain variable fragments (scFv) derived from distinct monoclonal antibodies, connected via a flexible peptide linker that enables simultaneous binding to two separate cellular targets.

One binding domain is specific for CD19, a transmembrane glycoprotein broadly expressed on B-lineage cells, including both normal B cells and malignant lymphoblasts. The second domain targets CD3, a key component of the T-cell receptor (TCR) complex present on cytotoxic T lymphocytes [8]. Through this dual specificity, blinatumomab functions as a molecular bridge, bringing T cells into close proximity with leukemic cells and facilitating the formation of an artificial immunological synapse.

CD19 plays a critical role as a co-receptor of the B-cell receptor (BCR) complex and is involved in the regulation of B-cell activation and intracellular signaling pathways. Its consistent expression across most

stages of B-cell development—from early precursors to mature B cells—makes it an optimal therapeutic target in B-cell precursor ALL [6].

From a clinical perspective, CD19-directed targeting enables selective depletion of malignant B cells while preserving the potential for immune reconstitution following treatment discontinuation. However, a major limitation of this approach is antigen escape, which represents a key mechanism of treatment failure and relapse.

Loss of CD19 expression may occur through several mechanisms, including clonal selection of CD19-negative subpopulations, genetic alterations affecting antigen expression, alternative splicing of CD19 transcripts, and epigenetic downregulation [18]. These processes have been observed in both blinatumomab- and CAR-T–treated patients, highlighting a shared vulnerability of CD19-targeted immunotherapies.

A distinctive structural feature of blinatumomab is the absence of an Fc fragment, which differentiates it from conventional monoclonal antibodies. This results in a reduced molecular size and a short serum half-life, necessitating continuous intravenous infusion. At the same time, the lack of an Fc region prevents complement activation and Fc-mediated effector functions [8]. While this limits classical immune effector pathways, it also contributes to a more controlled and predictable immune activation profile, reducing the risk of complement-mediated toxicity.

Mechanism of Action

The mechanism of action of blinatumomab involves a sequence of tightly coordinated immunological events that culminate in the targeted elimination of malignant cells. The central process is the formation of an artificial immunological synapse between a cytotoxic T lymphocyte and a CD19-positive leukemic cell [9].

Following simultaneous engagement of CD3 on T cells and CD19 on target cells, both cell types are brought into close spatial proximity. This interaction induces rapid T-cell activation in a major histocompatibility complex (MHC)-independent manner, which is particularly relevant in ALL, where tumor cells frequently evade immune surveillance through impaired antigen presentation.

Activated T cells undergo functional reprogramming characterized by clonal expansion, upregulation of adhesion molecules, secretion of pro-inflammatory cytokines such as IL-2, IFN-γ, and TNF-α, and release of cytotoxic granules containing perforin and granzymes [10]. Perforin mediates pore formation in the target cell membrane, allowing granzymes to enter the cytoplasm and initiate apoptotic signaling pathways.

This cytotoxic process is highly efficient, as a single activated T-cell is capable of sequentially eliminating multiple target cells, a phenomenon referred to as serial cytotoxicity. In addition, blinatumomab promotes recruitment and activation of additional T-cell populations, leading to progressive amplification of the immune response over time.

Immune checkpoint pathways also contribute to leukemic immune escape. Leukemic blasts may express programmed death-ligand 1 (PD-L1), which interacts with PD-1 receptors on T cells, resulting in functional exhaustion, reduced cytotoxic capacity, and impaired proliferative potential. Despite this immunosuppressive signaling, blinatumomab can partially overcome checkpoint-mediated inhibition by directly engaging CD3 and triggering T-cell activation independently of co-stimulatory signals [9,18].

This property enables effective cytotoxic responses even within a highly immunosuppressive tumor microenvironment.

In addition to direct cytotoxicity, emerging evidence suggests that blinatumomab may also influence the development of immunological memory. Activated T cells may differentiate into memory subsets, potentially contributing to sustained antitumor surveillance even after treatment discontinuation. This aspect, although not yet fully characterized, may have important implications for long-term disease control.

An additional aspect of blinatumomab activity involves the dynamic interaction between effector T cells and the tumor microenvironment over time. Following initial activation, T cells may undergo phenotypic and functional changes that influence the durability of response. These include differentiation into effector memory and central memory subsets, which may contribute to prolonged immune surveillance.

Moreover, the repeated formation of immunological synapses may lead to progressive amplification of the immune response, resulting in recruitment of additional immune cell populations. This process may partially explain sustained responses observed in some patients despite the relatively short half-life of the drug.

At the same time, continuous immune activation may also induce regulatory feedback mechanisms, including upregulation of inhibitory receptors and metabolic exhaustion, highlighting the delicate balance between effective cytotoxicity and immune regulation.

Advanced immunological interactions and tumor microenvironment modulation

Beyond direct T-cell engagement, blinatumomab exerts additional effects on the leukemic microenvironment. The formation of an artificial immunological synapse between CD3-positive T cells and CD19-positive leukemic blasts is stabilized by adhesion molecules such as LFA-1 and ICAM-1, which enhance cytotoxic efficiency and prolong synapse duration [7–9].

Activated T cells undergo metabolic reprogramming characterized by increased glycolytic activity and adaptation to mitochondrial stress, enabling sustained effector function within the bone marrow niche [8,9]. This metabolic shift is critical for maintaining cytotoxic activity in the otherwise suppressive leukemic microenvironment.

However, prolonged immune activation may contribute to T-cell exhaustion, characterized by progressive upregulation of inhibitory receptors such as PD-1, TIM-3, and LAG-3 [18]. This phenomenon may partially explain reduced therapeutic efficacy in heavily pretreated or relapsed patients.

In parallel, leukemic cells actively remodel the immune microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) and promoting the secretion of immunosuppressive cytokines, including IL-10 and TGF-β [2, 21]. These factors collectively impair sustained immune surveillance and may limit the durability of response to BiTE therapy.

A comprehensive understanding of these interactions is essential for the rational design of combination strategies aimed at enhancing T-cell persistence and overcoming immune exhaustion.

In addition to cellular interactions, soluble mediators within the bone marrow niche further modulate the response to therapy. Cytokine gradients, chemokine signaling, and metabolic constraints collectively shape the functional capacity of T cells. For example, hypoxic conditions and nutrient competition within the tumor microenvironment may limit sustained T-cell activity.

These factors highlight the importance of considering not only direct cell-to-cell interactions but also the broader ecological context in which immune responses occur. Understanding these complex dynamics may inform the development of combination strategies aimed at enhancing the efficacy of BiTE-based therapies.

Immunological basis of BiTE therapy

The clinical activity of blinatumomab should be interpreted within the broader framework of immuno-oncology, which aims to restore effective anti-tumor immune responses by overcoming tumor-associated immune evasion mechanisms. In ALL, leukemic blasts develop multiple strategies that enable immune escape and long-term persistence within the host.

These mechanisms include downregulation or loss of major histocompatibility complex (MHC) molecules, secretion of immunosuppressive cytokines, expansion of regulatory T cells (Tregs), and activation of immune checkpoint pathways, all of which contribute to the establishment of a profoundly immunosuppressive microenvironment.

In this context, blinatumomab retains therapeutic efficacy due to its distinct and non-conventional mode of action. Unlike physiological immune responses that depend on antigen processing and MHC-dependent presentation, blinatumomab directly links CD3-positive cytotoxic T cells with CD19-positive malignant B-lineage cells. This direct interaction enables rapid immune synapse formation and bypasses multiple layers of tumor immune evasion.

As a result, T-cell activation induced by blinatumomab is independent of classical antigen presentation, allowing efficient recognition and elimination of leukemic cells even in conditions of impaired antigen presentation and immune dysfunction [9]. This property is particularly relevant in relapsed or refractory ALL, where immune escape mechanisms are frequently amplified.

Immune checkpoint signaling represents another critical axis of leukemic immune evasion. Leukemic blasts may express PD-L1, which interacts with PD-1 receptors on activated T cells, leading to functional exhaustion, reduced cytokine production, and impaired proliferative capacity. Despite this inhibitory signaling, blinatumomab can partially overcome checkpoint-mediated suppression through direct CD3 engagement and robust T-cell activation [9, 18].

Collectively, these features position blinatumomab as a therapeutic approach capable of functionally bypassing multiple mechanisms of tumor immune resistance.

Pharmacokinetics and pharmacodynamics

The pharmacokinetic profile of blinatumomab differs substantially from that of conventional monoclonal antibodies. Due to its relatively small molecular weight (~55 kDa) and absence of an Fc fragment, the molecule does not undergo Fc-mediated recycling via the neonatal Fc receptor (FcRn), resulting in rapid systemic clearance and a short elimination half-life of approximately 2 hours [8]. Consequently, continuous intravenous infusion is required to maintain stable therapeutic exposure and sustained pharmacological activity.

The lack of an Fc domain also prevents classical effector mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), shifting the therapeutic effect exclusively toward T-cell–mediated cytotoxicity.

From a pharmacodynamic perspective, blinatumomab induces a rapid and profound immune response. This includes near-complete depletion of circulating CD19-positive B cells, transient redistribution and lymphopenia of T cells followed by expansion of activated effector T-cell populations, and an early increase in circulating pro-inflammatory cytokines.

Cytokine release, particularly involving IL-6, IFN-γ, and TNF-α, is closely associated with both therapeutic activity and toxicity, especially the development of cytokine release syndrome (CRS), reflecting a direct mechanism–toxicity relationship.

Importantly, the magnitude of cytokine release varies significantly between patients and appears to correlate with both tumor burden and baseline immune status. Patients with higher disease burden tend to exhibit more pronounced cytokine responses, which may increase the risk of toxicity but also reflect robust immune activation.

This relationship underscores the need for individualized dosing strategies and careful patient monitoring, particularly during the early phases of treatment. It also highlights the complex interplay between efficacy and toxicity, which represents a central challenge in immunotherapy.

Importantly, treatment efficacy is strongly influenced by tumor burden. Patients with lower disease load, particularly those with minimal residual disease (MRD), demonstrate superior responses. This observation is consistent with more efficient immune synapse formation and enhanced cytotoxic activity under conditions of reduced antigen burden and less pronounced immunosuppressive interference [4, 17].

Role of MRD in patient selection for Blinatumomab Therapy

Minimal residual disease (MRD) represents one of the most important prognostic factors in acute lymphoblastic leukemia ALL and plays a central role in therapeutic decision-making [4]. It is defined as the presence of leukemic cells below the detection threshold of conventional morphological assessment but detectable using highly sensitive methods such as multiparametric flow cytometry, allele-specific PCR, or next-generation sequencing.

These techniques enable detection of leukemic clones at levels as low as 10^{-4}–10^{-6}, allowing for a significantly more precise assessment of treatment response than standard hematological criteria.

MRD dynamics during and after therapy strongly correlate with clinical outcomes. Early MRD clearance is associated with a markedly reduced risk of relapse, whereas persistent or increasing MRD identifies patients with high-risk disease and inferior survival outcomes. Importantly, MRD functions not only as a static prognostic marker but also as a dynamic indicator of treatment response.

The increasing integration of MRD into clinical decision-making reflects a broader shift toward precision medicine in ALL. MRD-guided approaches enable dynamic adaptation of therapy intensity, allowing treatment escalation in high-risk patients while minimizing unnecessary toxicity in those achieving deep molecular responses.

In this context, blinatumomab has emerged as a highly effective therapeutic option for MRD-positive ALL. By facilitating direct engagement between CD3-positive T cells and CD19-positive leukemic blasts, it enables selective elimination of residual malignant cells that are often resistant to conventional chemotherapy.

Clinical studies have demonstrated that blinatumomab can induce deep molecular responses, with a substantial proportion of patients achieving MRD negativity following treatment [17]. This effect is particularly pronounced in patients with low tumor burden, where immune-mediated cytotoxicity is less constrained by microenvironmental immunosuppression.

Achievement of MRD negativity is now recognized as a key therapeutic endpoint, associated with improved overall survival, reduced relapse risk, and increased eligibility for allogeneic hematopoietic stem cell transplantation [4,17]. Consequently, MRD-guided strategies have become integral to modern ALL management, particularly in the era of targeted immunotherapies.

Clinical use in pediatric patients

The mechanistic and immunological properties of blinatumomab translate directly into its clinical applications in pediatric ALL.

Blinatumomab is approved for the treatment of pediatric patients with relapsed or refractory ALL, as well as for those with minimal residual disease (MRD)-positive status. Its clinical application in these settings is supported by multiple studies demonstrating substantial antileukemic activity combined with an acceptable and manageable safety profile [11].

Within contemporary treatment algorithms, blinatumomab occupies a distinct position between conventional multi-agent chemotherapy and advanced cellular therapies such as chimeric antigen receptor (CAR)-T cells, reflecting its role as both a salvage and bridging therapy.

In a phase II clinical trial conducted by von Stackelberg et al., blinatumomab induced complete remission in approximately 39% of pediatric patients with relapsed or refractory B-precursor ALL, with a considerable proportion achieving MRD negativity [12]. These findings are clinically significant, as MRD clearance is strongly associated with improved long-term outcomes, including event-free and overall survival.

Subsequent randomized trials comparing blinatumomab with standard chemotherapy have confirmed its superior efficacy, demonstrating higher response rates and improved survival outcomes, alongside a more favorable toxicity profile characterized by reduced incidence of severe hematological adverse events [13].

It is important to note that response rates reported in clinical trials should be interpreted in the context of patient selection and study design. Many trials include highly selected populations with defined eligibility criteria, which may not fully reflect real-world clinical scenarios.

Furthermore, the timing of blinatumomab administration within treatment algorithms may influence outcomes. Earlier use in the disease course, particularly in MRD-positive patients, appears to be associated with improved efficacy compared with use in advanced relapsed settings.

Importantly, blinatumomab has demonstrated considerable utility as a bridging strategy to allogeneic hematopoietic stem cell transplantation. By facilitating disease reduction and achieving MRD negativity prior to transplantation, it increases the proportion of patients eligible for curative treatment and may improve post-transplant outcomes [14].

Collectively, these findings support the integration of blinatumomab into modern pediatric ALL treatment strategies across multiple clinical scenarios.

Practical aspects of administration

Due to its short elimination half-life, blinatumomab is administered as a continuous intravenous infusion over 28 days, followed by a 14-day treatment-free interval. This dosing strategy is directly related to its pharmacokinetic properties and is required to maintain stable therapeutic exposure.

The need for continuous infusion introduces significant logistical complexity, necessitating the use of programmable infusion pumps and coordinated care between inpatient and outpatient settings. In pediatric populations, this requires close collaboration between healthcare providers and caregivers to ensure treatment adherence, safety, and appropriate monitoring [15].

Clinical monitoring is particularly critical during the initial phase of therapy, when immune activation is most pronounced and the risk of cytokine release syndrome (CRS) is highest [16]. Cytokine release syndrome (CRS), discussed in detail below, represents a key early toxicity associated with treatment initiation.

Neurological toxicity represents another clinically significant concern. Manifestations range from mild symptoms, such as headache and confusion, to severe complications including seizures, encephalopathy, and speech disturbances. Although the underlying pathophysiology is not fully understood, it is thought to involve cytokine-mediated neuroinflammation and immune cell trafficking across the blood–brain barrier.

For this reason, regular neurological assessment is required throughout treatment, particularly during the early infusion period. Prompt recognition and appropriate management of symptoms are essential to minimize morbidity and ensure treatment continuity [4, 17].

Safety profile and adverse events

Blinatumomab exhibits a distinct safety profile compared with conventional cytotoxic chemotherapy, reflecting its mechanism of action based on T-cell activation through simultaneous binding to CD3 on T lymphocytes and CD19 on B-lineage cells [7–9].

The most clinically significant adverse event is cytokine release syndrome (CRS), which results from rapid immune activation and subsequent release of pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-10 (IL-10), and interferon-gamma. Clinically, CRS typically presents with fever, hypotension, tachycardia, and hypoxia, and in severe cases may progress to multi-organ dysfunction [15].

In pediatric patients, CRS most frequently occurs during the initial phase of treatment and is generally mild to moderate in severity, as demonstrated in clinical studies [12]. Its incidence and severity can be significantly reduced through stepwise dose escalation and prophylactic administration of corticosteroids.

Neurological toxicity constitutes the second major category of adverse events. The clinical spectrum ranges from mild symptoms, such as headache and dizziness, to severe manifestations including encephalopathy, seizures, and impaired consciousness [14,16]. Although the exact mechanisms remain incompletely understood, current evidence suggests a multifactorial process involving cytokine-mediated neuroinflammation and immune cell migration across the blood–brain barrier.

Importantly, in most cases these neurological events are reversible and resolve following temporary treatment interruption or discontinuation.

Compared with multi-agent chemotherapy, blinatumomab is associated with reduced myelosuppression, resulting in a lower incidence of severe neutropenia and bleeding complications [6,13]. However, patients remain at increased risk of infections due to both underlying disease-related immunodeficiency and therapy-induced immune modulation.

Overall, the safety profile of blinatumomab is considered predictable and manageable when appropriate monitoring and supportive care strategies are implemented.

From a clinical perspective, the management of these adverse events has significantly improved over time, largely due to increased experience and the development of standardized treatment protocols. Early recognition and prompt intervention are critical in minimizing complications and ensuring treatment continuity.

Importantly, the overall risk-benefit profile of blinatumomab remains favorable, particularly when compared with the toxicity associated with intensive chemotherapy regimens.

Real-world outcomes versus clinical trial data

Although clinical trials provide robust evidence supporting the efficacy of blinatumomab, real-world studies have demonstrated greater variability in treatment outcomes. In routine clinical practice, patient populations are typically more heterogeneous, including individuals with comorbidities, extensive prior treatment exposure, and variable immune competence [13,16].

Real-world data suggest that remission rates may be modestly lower than those reported in controlled clinical trials, particularly among heavily pretreated patients with relapsed or refractory disease [12,13]. This discrepancy is likely multifactorial, reflecting differences in patient selection, supportive care, and monitoring intensity.

Despite these differences, real-world evidence consistently confirms the favorable safety profile of blinatumomab. Adverse events such as CRS and neurotoxicity are generally manageable using standardized treatment protocols, including corticosteroid premedication and stepwise dose escalation [15,16].

Importantly, the successful translation of these management strategies into routine clinical practice has contributed to improved treatment tolerability and broader applicability across diverse healthcare settings.

Additionally, variability in healthcare infrastructure, access to specialized centers, and experience with immunotherapy may further influence treatment outcomes, particularly in resource-limited settings.

These findings underscore the importance of integrating clinical trial data with real-world evidence to achieve a comprehensive understanding of the therapeutic profile of blinatumomab.

Advantages and limitations of therapy

Despite its clinical efficacy, a comprehensive evaluation of blinatumomab requires consideration of both its advantages and inherent limitations.

Blinatumomab represents a major advancement in the treatment of acute lymphoblastic leukemia, offering several clinically relevant advantages over conventional multi-agent chemotherapy. Its principal strength lies in the selective targeting of CD19-positive leukemic cells, enabling highly specific immune-mediated cytotoxicity while minimizing off-target effects. This targeted mechanism translates into improved therapeutic efficacy combined with a reduction in systemic toxicity.

A particularly important advantage is its demonstrated activity against minimal residual disease (MRD), one of the strongest prognostic factors in ALL and a key determinant of long-term outcomes [13,18]. The ability to achieve deep molecular remission has significant implications for survival and for eligibility for curative treatment strategies such as hematopoietic stem cell transplantation.

Despite these benefits, several limitations must be considered. Immune-mediated toxicities, including cytokine release syndrome (CRS) and neurotoxicity, remain clinically relevant and require careful monitoring and management. In addition, the need for continuous intravenous infusion represents a significant logistical burden, potentially affecting patient quality of life and healthcare resource utilization.

Economic considerations also play a role, as the high cost of therapy may limit accessibility in certain healthcare systems. Furthermore, the development of treatment resistance—most notably through loss or downregulation of CD19 expression—remains a major challenge and a key mechanism underlying disease relapse [19].

Overall, while blinatumomab offers clear therapeutic advantages, its optimal use requires careful patient selection and integration into broader treatment strategies.

Predictive factors of response to Blinatumomab Therapy

Identification of predictive factors associated with response to blinatumomab is essential for optimizing treatment strategies in ALL. Treatment outcomes are influenced by a combination of disease-related, immunological, and microenvironmental variables.

Among these, minimal residual disease (MRD) status and overall tumor burden represent the most important determinants. Patients with low disease burden, particularly those with MRD-positive status, consistently demonstrate superior responses, likely due to more efficient immune synapse formation and reduced immunosuppressive interference [17].

The functional status of the patient's T-cell compartment is another critical factor. In heavily pretreated individuals, T-cell exhaustion or dysfunction may significantly impair cytotoxic activity, thereby limiting the effectiveness of BiTE-mediated immune engagement.

In addition, genetic characteristics of leukemic cells and features of the bone marrow microenvironment contribute to inter-patient variability in response. These factors influence both immune activation and immune escape mechanisms, ultimately shaping therapeutic outcomes [2,21].

A more comprehensive understanding of these determinants may support the development of personalized treatment approaches in the future.

Resistance to Blinatumomab: mechanisms and therapeutic strategies

Despite its high clinical efficacy, resistance to blinatumomab remains an important challenge in the management of ALL. The most well-characterized mechanism is the loss or downregulation of CD19 expression on leukemic blasts, leading to impaired immune recognition and treatment failure [18].

However, resistance is a multifactorial process involving both tumor-intrinsic and immune-related mechanisms. These include T-cell exhaustion, impaired immune synapse formation, alterations in the bone marrow microenvironment, and increased expression of immunosuppressive molecules.

Current strategies aimed at overcoming resistance focus on several complementary approaches. These include the development of next-generation bispecific antibodies with improved binding properties, targeting of alternative antigens beyond CD19, and combination therapies designed to enhance T-cell activation while counteracting immune suppression.

Such strategies aim to restore effective immune surveillance and improve the durability of therapeutic responses.

Comparison with other treatment modalities

The treatment of pediatric ALL has traditionally relied on intensive multi-agent chemotherapy, achieving cure rates of approximately 80–90% in newly diagnosed patients [1,2]. However, outcomes remain significantly poorer in relapsed or refractory disease.

Blinatumomab represents a major therapeutic innovation in this context. Clinical studies have demonstrated its superiority over standard chemotherapy in relapsed or refractory ALL, particularly in terms of remission rates and event-free survival [6,13]. Moreover, its ability to induce deep molecular remission further supports its clinical relevance.

Compared with conventional chemotherapy, blinatumomab is associated with a more favorable toxicity profile, particularly due to reduced myelosuppression and lower rates of organ toxicity. However, its administration requires continuous infusion, which introduces logistical challenges.

Within the broader immunotherapeutic landscape, blinatumomab differs from chimeric antigen receptor (CAR)-T cell therapy, which involves ex vivo genetic modification of autologous T cells. CAR-T therapy has demonstrated very high remission rates, even in heavily pretreated patients, but is associated with increased toxicity, greater complexity, and higher cost [19,20].

Antibody–drug conjugates, such as inotuzumab ozogamicin, represent an alternative approach based on targeted delivery of cytotoxic agents independent of T-cell activation. These therapies are often used in sequential or combination strategies in relapsed disease.

A shared limitation across CD19-targeted therapies, including both blinatumomab and CAR-T approaches, is antigen escape, which remains a major driver of relapse [18].

Overall, blinatumomab occupies an intermediate position between conventional chemotherapy and advanced cellular therapies, offering a balance between efficacy, safety, and feasibility.

An additional consideration is the difference in treatment accessibility and logistical requirements between these modalities. While CAR-T therapy requires complex manufacturing processes and specialized infrastructure, blinatumomab can be administered more readily in a wider range of clinical settings.

However, the need for continuous infusion may still limit its practicality in certain contexts, particularly in healthcare systems with limited outpatient support.

These differences highlight the importance of tailoring treatment selection not only to disease characteristics but also to patient-specific and system-level factors.

Clinical positioning of Blinatumomab in Therapeutic Algorithms

The integration of blinatumomab into current treatment algorithms reflects a broader shift toward response-adapted and MRD-guided therapy in ALL [4,17].

In patients with newly diagnosed high-risk disease, blinatumomab is not yet universally established as first-line therapy; however, emerging evidence supports its incorporation into consolidation phases, particularly in MRD-positive cases following induction treatment [11,17].

In relapsed or refractory ALL, blinatumomab serves as a key bridging therapy to hematopoietic stem cell transplantation, increasing the likelihood of achieving disease control prior to transplantation and improving eligibility for curative treatment approaches [14].

Compared with CAR-T therapy, blinatumomab offers the advantage of immediate availability, without the need for complex manufacturing processes. Conversely, CAR-T therapy may be preferred in cases of multiple relapse or blinatumomab failure, particularly in patients with preserved T-cell function [19,20].

Future treatment strategies are likely to incorporate functional immune profiling, MRD kinetics, and antigen expression patterns, supporting a transition toward more personalized therapeutic algorithms.

Limitations of current evidence

Despite substantial progress, several limitations of the current evidence base should be acknowledged. Most available data derive from phase II and phase III clinical trials with relatively small pediatric cohorts, which may limit generalizability [12,13].

Heterogeneity in patient populations, including differences in prior therapies, disease burden, and MRD status, complicates cross-study comparisons. In particular, MRD-positive patients represent a biologically distinct subgroup, which may influence perceived treatment efficacy [17].

Long-term follow-up data remain limited, particularly with respect to late relapse, immune reconstitution, and neurocognitive outcomes [14,16]. In addition, most studies focus on CD19-positive disease,

while emerging evidence suggests that antigen escape and lineage switching may alter disease biology under therapeutic pressure [18].

Finally, real-world data remain relatively limited, especially regarding optimal sequencing with CAR-T therapy and transplantation strategies [19,20]. These gaps highlight the need for ongoing prospective studies and long-term observational data.

Another important limitation is the potential for publication bias, as studies reporting positive outcomes are more likely to be published. This may lead to an overestimation of treatment efficacy in the available literature.

Future directions in Blinatumomab Therapy

Ongoing research is focused on expanding the clinical applications of blinatumomab and optimizing its therapeutic potential. Increasing attention is being directed toward its incorporation into earlier treatment phases, including frontline and consolidation strategies in high-risk patients.

Combination approaches represent a key area of development. The integration of blinatumomab with reduced-intensity chemotherapy, targeted agents such as tyrosine kinase inhibitors, or immune checkpoint inhibitors may enhance therapeutic efficacy while minimizing toxicity.

Another emerging area of interest is the combination of blinatumomab with immune checkpoint inhibitors. Given the central role of PD-1/PD-L1 signaling in T-cell exhaustion, dual-targeting strategies may enhance T-cell persistence and improve long-term therapeutic efficacy.

Furthermore, advances in genomic and transcriptomic profiling may enable identification of novel predictive biomarkers associated with response or resistance to therapy. Integration of such approaches into clinical practice could facilitate more precise patient selection and optimization of treatment strategies.

The use of blinatumomab as a bridging strategy to hematopoietic stem cell transplantation is also being further refined, with particular emphasis on achieving deep molecular remission prior to transplantation.

In parallel, next-generation bispecific antibodies targeting alternative antigens are under development, aiming to overcome resistance mechanisms such as CD19 antigen loss [7].

Future research priorities include optimization of dosing strategies, identification of robust predictive biomarkers, and integration of genomic and immunological profiling into precision medicine approaches [7,19].

Another promising direction involves the development of next-generation BiTE molecules with extended half-life, which may eliminate the need for continuous infusion and improve patient convenience. Modifications in molecular design may also enhance binding affinity and optimize T-cell activation.

Additionally, integration of artificial intelligence and machine learning approaches may support prediction of treatment response and identification of optimal therapeutic strategies based on complex clinical and biological datasets.

Conclusions

Taken together, these findings highlight the evolving role of blinatumomab in modern ALL therapy.

Blinatumomab represents a significant advancement in the treatment of pediatric acute lymphoblastic leukemia and a key component of modern immunotherapy for hematologic malignancies. Its unique mechanism of action, based on simultaneous engagement of CD3-positive T lymphocytes and CD19-positive leukemic cells, enables highly effective immune-mediated cytotoxicity independent of conventional antigen presentation pathways.

Clinically, blinatumomab plays a particularly important role in patients with minimal residual disease (MRD) and in relapsed or refractory ALL, where it facilitates the achievement of deep molecular remission and improves eligibility for curative treatment strategies such as hematopoietic stem cell transplantation.

Compared with conventional chemotherapy, it offers a more favorable toxicity profile, which is especially relevant in pediatric populations. However, its use is associated with specific limitations, including immune-mediated adverse events, the requirement for continuous infusion, and the risk of treatment resistance.

Within the current therapeutic landscape, blinatumomab occupies an intermediate position between chemotherapy and advanced cellular therapies such as CAR-T cells, providing a clinically relevant balance between efficacy, safety, and feasibility.

Ongoing research aimed at optimizing its use, overcoming resistance mechanisms, and integrating it into personalized treatment strategies is expected to further improve outcomes in pediatric ALL.

Overall, blinatumomab represents a cornerstone of contemporary ALL therapy and an important step toward more precise and effective immunotherapeutic approaches.

As the field of immunotherapy continues to evolve, blinatumomab is likely to remain an integral component of treatment strategies, particularly as part of combination approaches and personalized medicine frameworks.

Its role in bridging conventional and advanced therapies underscores its importance in the ongoing transformation of ALL treatment paradigms.

The authors declare that they have no conflict of interest.

This research received no external founding.

All authors contributed to the study conception, literature review, and manuscript preparation. All authors read and approved the final version of the manuscript.

REFERENCES

1. Pui, C. H., Robison, L. L., & Look, A. T. (2008). Acute lymphoblastic leukaemia. *The Lancet, 371*(9617), 1030–1043. https://doi.org/10.1016/S0140-6736(08)60457-2
2. Hunger, S. P., & Mullighan, C. G. (2015). Acute lymphoblastic leukemia in children. *The New England Journal of Medicine, 373*(16), 1541–1552. https://doi.org/10.1056/NEJMra1400972
3. Szczepański, T. (2022). Ostra białaczka limfoblastyczna u dzieci. In J. Styczyński & M. Matysiak (Eds.), *Hematologia i onkologia dziecięca dla lekarzy praktyków* (pp. 257–259). Wydawnictwo Czelej.
4. Campana, D. (2010). Minimal residual disease in acute lymphoblastic leukemia. *Hematology. American Society of Hematology. Education Program, 2010*(1), 7–12. https://doi.org/10.1182/asheducation-2010.1.7
5. Al-Mawali, A., Gillis, D., Hissaria, P., & Lewis, I. (2008). Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. *American Journal of Clinical Pathology, 129*(6), 934–945. https://doi.org/10.1309/FY0UMAMM91VPMR2W
6. Kantarjian, H., Stein, A., Gökbuget, N., et al. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. *The New England Journal of Medicine, 376*(9), 836–847. https://doi.org/10.1056/NEJMoa1609783
7. Bargou, R., Leo, E., Zugmaier, G., et al. (2008). Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. *Science, 321*(5891), 974–977. https://doi.org/10.1126/science.1158545
8. Offner, S., Hofmeister, R., Romaniuk, A., et al. (2006). Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. *Molecular Immunology, 43*(6), 763–771. https://doi.org/10.1016/j.molimm.2005.03.007
9. Dreier, T., Lorenczewski, G., Brandl, C., et al. (2002). Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. *Journal of Immunology, 168*(11), 5540–5547. https://doi.org/10.4049/jimmunol.168.11.5540
10. Klinger, M., Brandl, C., Zugmaier, G., et al. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. *Leukemia, 26*(6), 1215–1221. https://doi.org/10.1038/leu.2011.158
11. U.S. Food and Drug Administration. (2024). *FDA approves blinatumomab as consolidation therapy for B-ALL*. https://www.fda.gov
12. von Stackelberg, A., Locatelli, F., Zugmaier, G., et al. (2016). Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Journal of Clinical Oncology, 34*(36), 4381–4389. https://doi.org/10.1200/JCO.2016.67.3301
13. Brown, P. A., Ji, L., Xu, X., et al. (2021). Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. *JAMA, 325*(9), 833–842. https://doi.org/10.1001/jama.2021.0669
14. Topp, M. S., Gökbuget, N., Stein, A. S., et al. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. *The Lancet Oncology, 16*(1), 57–66. https://doi.org/10.1016/S1470-2045(14)71170-2
15. Lee, D. W., Gardner, R., Porter, D. L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. *Blood, 124*(2), 188–195. https://doi.org/10.1182/blood-2014-05-552729
16. Zugmaier, G., Gökbuget, N., Klinger, M., et al. (2015). Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. *Blood, 126*(24), 2578–2584. https://doi.org/10.1182/blood-2015-06-650986

17. Gökbuget, N., Dombret, H., Bonifacio, M., et al. (2017). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. *Blood, 129*(12), 1602–1609. https://doi.org/10.1182/blood-2016-08-737379
18. Orlando, E. J., Han, X., Tribouley, C., et al. (2018). Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. *Nature Medicine, 24*(10), 1504–1506. https://doi.org/10.1038/s41591-018-0146-z
19. June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. *The New England Journal of Medicine, 379*(1), 64–73. https://doi.org/10.1056/NEJMra1706169
20. Grupp, S. A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. *The New England Journal of Medicine, 368*(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134
21. Bassan, R., & Hoelzer, D. (2011). Modern therapy of acute lymphoblastic leukemia. *Journal of Clinical Oncology, 29*(5), 532–543. https://doi.org/10.1200/JCO.2010.30.1382
22. Kantarjian, H., Stelljes, M., Martinelli, G., et al. (2016). Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. *The New England Journal of Medicine, 375*(8), 740–753. https://doi.org/10.1056/NEJMoa1509277